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Hyperglycemia was reported to enhance angiotensin
(Ang) II generation in rat cardiomyocytes, and Ang II
inhibition reduces cardiovascular morbidity and mortal-
ity in diabetic patients. In diabetic patients, the en-
hanced activation of intracellular pathways related with
myocyte hypertrophy and gene expression might en-
hance the progression of cardiac damage. Therefore, we
investigated the effects of glucose on Ang II–mediated
activation of Janus-activated kinase (JAK)-2, a tyrosine
kinase related with myocyte hypertrophy and cytokine
and fibrogenetic growth factor overexpression, in ven-
tricular myocytes isolated from nonfailing human
hearts (n  5) and failing human hearts (n  8). In
nonfailing myocytes, JAK2 phosphorylation was en-
hanced by Ang II only in the presence of high glucose
(25 mmol/l) via Ang II type I (AT1) receptors (79% vs.
normal glucose, P < 0.05). JAK2 activation was pre-
vented by inhibitors of reactive oxygen species (ROS)
generation (diphenyleneiodonium [DPI], tiron, and apo-
cynin). In myocytes isolated from failing hearts, JAK2
phosphorylation was enhanced by high glucose alone
(107%, P < 0.05). High glucose–induced JAK2 activa-
tion was blunted by both ACE inhibition (100 nmol/l
ramipril) and AT1 antagonism (1 mol/l valsartan),
thus revealing that the effects are mediated by auto-
crine Ang II production. Inhibition of ROS generation
also prevented high glucose–induced JAK2 phosphory-
lation. In conclusion, in human nonfailing myocytes,
high glucose allows Ang II to activate JAK2 signaling,
whereas in failing myocytes, hyperglycemia alone is able
to induce Ang II generation, which in turn activates
JAK2 via enhanced oxidative stress. Diabetes 54:
394–401, 2005
In patients with diabetes and abnormal glucose tol-erance, left ventricular hypertrophy is often detect-able (1,2) and diastolic dysfunction is highlyprevalent (3). Diabetic cardiomyopathy, character-
ized by both myocyte hypertrophy and enhanced collagen
deposition (4), is almost invariably followed by the transi-
tion into a dilated form with depressed contractile behav-
ior and heart failure irrespective of coronary heart disease
and hypertension (4,5).
A direct link was found among glucose, angiotensin
(Ang) II, reactive oxygen species (ROS) generation, and
the transmission of death signaling in rat myocytes (p38
mitogen-activated protein kinase [MAPK]). Indeed, the
glycosylation of O-linked N-acetylglucosamine may acti-
vate p53 in cardiomyocytes, thus enhancing angiotensino-
gen (AGTN) transcription and Ang II formation (6), which
is finally responsible for the activation of death-related
intracellular signaling pathways (4,6). In these experimen-
tal studies, hyperglycemia-induced Ang II formation failed
to activate extracellular signal–related kinase (ERK)-1/2
(6), a MAPK playing a well-accepted role in the hypertro-
phic response of cardiomyocytes (7,8), so that the possible
relationship between glucose and Ang II in diabetic myo-
cyte hypertrophy remains elusive.
In other cell types, the signaling cascade linking the
activation of the nuclear transcriptional changes and cell
growth to Ang II type I (ATI) receptor stimulation was
found to include the phosphorylation of Janus-activated
kinase (JAK)-2, a soluble tyrosine kinase (9) also involved
in the transmission of the inflammatory processes (10).
Ang II–mediated JAK2 activation in vitro was also found to
critically require ROS generation via the membrane-bound
NADPH oxidase system (10). However, the capability of
Ang II to induce JAK2 phosphorylation in cardiomyocytes
was observed only in neonatal rat cells (11–13), whereas
no information is available in adult ventricular myocytes.
In rat mesangial cells, Ang II–mediated JAK2 activation
in vitro was found to be enhanced in the presence of high
glucose concentration (14), and high glucose is known to
enhance both ROS generation (15) and Ang II formation
(6). However, although there have been several studies
showing that high glucose potentiates local renin-angio-
tensin system (RAS) in cardiomyocytes of experimental
animals, no study was conducted in human ventricular
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myocytes, and the mechanism for activated local RAS in
that condition remains elusive. It has been shown that
chymase rather than ACE is a major determinant for local
Ang II generation in the canine (16), baboon (17), and
human (18) hearts. These observations tend to minimize
the role of ACE in the conversion of Ang I to Ang II in
human heart failure. However, opposite results have also
been reported (19), and ACE, rather than chymase, was
found to be overexpressed in human failing hearts (20).
One of the problems with these findings is that little
attention has been given to myocytes even though the
entire myocardium or the properties of the interstitial fluid
have been analyzed (16–20).
In this article, the hypothesis was raised that glucose
and Ang II might interact to enhance NADPH oxidase
activation and JAK2 phosphorylation in human ventricular
myocytes. In particular, we investigated whether high
glucose may enhance JAK2 activation in human myocytes,
the role played by Ang II, and the pathways involved in high
glucose–enhanced Ang II formation in failing myocytes.
RESEARCH DESIGN AND METHODS
Myocytes were obtained from the hearts of five putative organ donors (aged
47  5 years) with no histories or signs of heart disease and whose hearts
could not be transplanted because of noncardiac reasons (“nonfailing hearts”)
and of eight patients (aged 53  11 years) with end-stage dilated cardiomy-
opathy scheduled to undergo cardiac transplantation. Characteristics of
subjects investigated are reported in Table 1.
Subjects with arterial hypertension, history of myocardial infarction, and
echocardiographic evidence of valve or congenital heart disease were not
considered for the study. Diagnosis of dilated cardiomyopathy was based on
clinical and echocardiographic examination. Myocardial tissue was obtained
from a portion of the left ventricular free wall during cardiac transplantation.
The protocol of this study complies with the principles of the Helsinki
Declaration and was approved by our institution (University of Florence). All
patients gave their informed written consent to participate and to have their
hearts used for the study.
Myocyte isolation. Myocytes were isolated with the enzymatic digestion
method as previously described (20). Briefly, a coronary artery branch was
cannulated and perfused for 10 min with a calcium-free buffer (blood
washout) and then with collagenase (Worthington-type II, 100 units/ml, 20
ml/min). The collagenase-perfused tissue was then minced and shaken in a
resuspension buffer (HEPES-MEM buffer supplemented with bovine serum
albumin 0.5%, 0.3 mmol/l CaCl2, and 10 mmol/l taurine). Myocytes were then
collected and enriched by centrifugation for 4 min at 35g. Cells were then
suspended in isotonic Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden)
at a final concentration of 41% and centrifuged for 10 min at 34g. Pellets were
washed and smears were made (Fig. 1). Rod-shaped, trypan blue–excluding
cells constituted nearly 80% of all myocytes. Nonmyocytes accounted for2%
of the cells (20).
Receptor binding studies. Equilibrium binding studies were performed by
incubating freshly isolated myocytes (1  106 cell/ml) with 100 pmol/l of
[125I]Ang II (2,000 Ci/mmol; Amersham Biosciences, Uppsala, Sweden) and
increasing concentrations of unlabeled Ang II (0–100 mol/l) at 22°C for 90
min as previously described (20). Ang II receptor subtypes were characterized
FIG. 1. Myocytes from the left ventricle of a patient
with dilated cardiomyopathy.
TABLE 1
Characteristics of subjects investigated
Nonfailing
Dilated
cardiomyopathy
Age (years) 47 5 53 11
Sex (M/F) 4/1 7/1
Body surface area (m2) 1.81 0.13 1.83 0.26
New York Heart Association
class (III/IV) — 6/2
Left ventricular end diastolic
diameter index (mm/m2) 26.1 3.6 44.1 6.7*
Left ventricular mass index
(g/m2) 101 16 266 49*
Ejection fraction (%) 63 3.2 19 7.5*
Cardiac index (l  m2 
min1) — 2.03 0.40
Mean pulmonary artery
pressure (mmHg) — 22.7 8.6
Left ventricular end diastolic
pressure (mmHg) — 19.4 7.3
Pulmonary capillary wedge
pressure (mmHg) — 14 4
End systolic stress
(kdyne/cm2) — 99 18
End diastolic stress
(kdyne/cm2) — 22 5
Data are means  SE. *P  0.01 vs. control subjects.
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using selective antagonists for AT1 (valsartan, a kind gift of Novartis, Italy)
and Ang II type II (AT2) receptors (PD123319). Binding data were analyzed by
a nonlinear fitting computer program (LIGAND).
RT-PCR. To document the presence of transcripts for the two Ang receptor
subtypes, for other local RAS components, and for chymase in human
ventricular nonfailing and failing myocytes, total mRNA was extracted with
TRIzol reagent (BRL-Life Technologies), as indicated by the manufacturer,
and reverse-transcribed using oligo dT as previously reported (20). The
resulting cDNA was amplified using specific primers for AGTN (20), ACE (21),
AT1 receptor (22), AT2 receptor (22), chymase (18), and GAPDH used as
internal standard (20). To ensure that different amounts of PCRs on myocar-
dial biopsies were not due to markedly different mRNA starting concentra-
tions, PCR analysis for GAPDH was performed on serial twofold dilutions of
cDNA for each sample. The last dilution giving a positive reaction for GAPDH
was used to equalize the amount of cDNA used in each PCR.
PCRs were performed in a DNA Thermal Cycler (Perkin Elmer Cetus),
band densities were analyzed using a computer image densitometer (Qwin;
Leica), and the densitometric ratio to GAPDH was calculated for each
transcript (20).
Incubation of myocytes with high glucose or Ang II. Freshly isolated
myocytes (105 cell/ml) from both nonfailing and dilated cardiomyopathy
hearts were suspended in Dulbecco’s minimal essential medium (DMEM) (pH
7.4) and in the absence of insulin. After 30 min, the medium was changed with
DMEM containing 5.5 mmol/l (normal glucose) or 25 mmol/l glucose (high
glucose) corresponding to plasma levels of 100 and 450 mg/dl, respectively.
Hyperosmolarity was corrected by decreasing salts (final osmolarity 322
mOsm/kg), and acidosis was corrected by adding 20 mmol/l HEPES. In
separate experiments, the effect of osmolarity was checked by adding 19.5
mmol/l of mannitol or glucose to normal glucose buffer. The medium was
supplemented with 100 units/ml penicillin G and 0.1 mg/ml streptomycin. The
cells were incubated under an atmosphere of 95% air plus 5% CO2 at 37°C for
2, 6, and 12 h.
To investigate the relative role of Ang II receptor subtypes and the
involvement of the RAS in high glucose–induced JAK2 activation, myocytes
were preincubated with selective AT1 (1 mol/l valsartan) or AT2 (1 mol/l
PD123319) receptor antagonists and with an ACE inhibitor (100 nmol/l
ramipril).
In addition, to try to characterize ROS induced by Ang II, we performed
experiments in the presence of a cell-permeable superoxide anion scavenger
(100 mol/l tiron), a flavoprotein inhibitor (100 mol/l diphenyleneiodonium
[DPI]), an inhibitor of NADPH oxidase system (10 mol/l apocynin), and an
inhibitor of mitochondrial ROS production (5 mol/l rotenone).
These compounds were added 30 min before glucose. Preliminary exper-
iments revealed that the incubation of myocytes with tiron, diphenyleneiodo-
nium (DPI), apocynin, and rotenone in the absence of Ang II and in normal
glucose did not cause any nonspecific effect on JAK2 phosphorylation status.
To investigate whether glucose may affect Ang II signaling, myocytes were
then coincubated with Ang II (100 nmol/l) in the presence of AT1 or AT2
receptor antagonists, tiron, DPI, apocynin, and rotenone at the concentrations
reported above, with normal glucose or high glucose. Myocytes were then
separated and frozen at 80°C.
Western blot. Myocytes were then suspended in ice-cold lysis buffer (10
nmol/l Tris-HCl, 20 mmol/l NaCl, 1 mmol/l sodium orthovanadate, 10 mmol/l
sodium pyrophosphate, 10 mmol/l okadaic acid, 2 mmol/l EGTA, 2 mmol/l
dithiotreitol, and 1 mmol/l phenylmethylsulfonyl fluoride, pH 7.4). Lysates
were kept on ice, sonicated four times for 5 s, and centrifuged for 10 min at
13,000g. Protein concentration in the supernatant fraction was assessed by the
Bradford’s method.
Samples (25 g proteins) were then separated by 8% SDS-PAGE. The gel
was then transferred to nitrocellulose membrane (Hybond-ECL, Amersham
Biosciences) and blocked by 1-h incubation at room temperature in TTBS
(Tris-buffered saline with 0.05% Tween 20, pH 7.4) plus 5% skimmed milk
powder. The nitrocellulose membrane was incubated overnight at 4°C with
anti-human phospho-JAK2 (Upstate) or anti-human JAK2 antibodies (Santa
Cruz). Then the nitrocellulose membrane was washed twice for 10 min with
TTBS and incubated for 30 min with goat anti-rabbit IgG horseradish
peroxidase conjugate antibody (Amerham Biosciences). After extensive wash-
ing, the bound antibody was visualized by a chemiluminescent detection
system.
Positive control was performed by stimulating nonfailing myocytes with
interleukin 6 (10 ng/ml). Negative controls were obtained both in the presence
of competing peptide (Santa Cruz SC16566P) and with no first-antibody
control lane.
Data analysis. Data are reported as means  SD. Autoradiograms were
analyzed by an image analyzer. All statistical comparisons were made using
Student’s t test for paired data and ANOVA. Significance was P  0.05.
RESULTS
Effect of high glucose on Ang II–induced JAK2 acti-
vation in nonfailing myocytes. Incubation of myocytes
isolated from nonfailing hearts in the presence of high
glucose concentration (25 mmol/l) had no effect on JAK2
tyrosine phosphorylation (Fig. 2).
To investigate whether glucose may affect Ang II signal-
ing, nonfailing myocytes were stimulated with Ang II in the
presence of both normal glucose and high glucose. Ang II
did not enhance JAK2 phosphorylation in nonfailing myo-
cytes in the presence of normal glucose concentrations
(NS vs. baseline) (Fig. 2). Conversely, when myocytes
were preincubated in the presence of high glucose, Ang II
caused a significant increase in JAK2 phosphorylation at
6-h (79% vs. normal glucose, P  0.05) concentrations
(Fig. 2).
The lack of response observed in the presence of
mannitol and the comparable effects of high glucose on
JAK2 phosphorylation at normal and high final osmolarity
(Fig. 3) indicate that the effect of glucose is independent of
either reduction of salt content or osmolarity changes.
The effect is mediated by AT1 receptor as shown by the
inhibitory effect of valsartan (1 mol/l) (Fig. 4) on Ang
II–induced JAK2 activation (61%, P  0.01 for both).
Conversely, AT2 antagonism did not cause any significant
effect on Ang II–induced JAK2 phosphorylation (Fig. 4).
The coincubation with a flavoprotein inhibitor (DPI)
FIG. 2. A: Effect of Ang II (100 nmol/l) on the phosphorylated–to–total
JAK2 ratio in the presence of normal (E) (5.5 mmol/l) or high glucose
(F) (*P < 0.01 vs. normal glucose). In high glucose, osmolarity was
kept normal (322 mOsm/kg) by reducing salt content. Data are
means  SD. B: Representative Western blots performed by using
specific anti–human-phospho-JAK2 (p-JAK2) and anti-JAK2 (JAK2)
antibodies on lysated myocytes at baseline and after 2, 6, and 12 h of
incubation with normal or high glucose in the absence and in the
presence of Ang II (100 nmol/l).
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prevented Ang II–induced JAK2 phosphorylation in high
glucose conditions (P  0.05 vs. Ang II) (Fig. 4), thus
suggesting that JAK2 activation is mediated by ROS gen-
eration. Ang II–induced JAK2 phosphorylation in high
glucose conditions was also inhibited by tiron, apocynin,
and rotenone (Fig. 5).
Glucose induces JAK2 phosphorylation in failing
myocytes. Differently from nonfailing myocytes, myo-
cytes isolated from failing hearts responded to high glu-
cose with a significant increase in the level of JAK2
tyrosine phosphorylation (207% vs. baseline, P  0.05)
(Fig. 6). Equal amounts of the nonphosphorylated form of
JAK2 were detected in all samples (Fig. 6).
Ang II mediates the glucose-induced JAK2 phosphor-
ylation in failing myocytes. Unlike that observed in
nonfailing cells, Ang II induced JAK2 phosphorylation in
failing myocytes also when the cells were incubated in the
presence of normal glucose (Fig. 7).
To evaluate whether the high glucose–induced JAK2
phosphorylation was mediated by Ang II, myocytes were
preincubated with AT1 (valsartan) or AT2 (PD123319)
receptor antagonists. Valsartan significantly inhibited by
43% (Fig. 7) the high glucose–induced JAK2 phosphoryla-
tion in failing myocytes (P  0.01 for both). Conversely,
PD123319 did not affect glucose induced JAK2 phosphor-
ylation (Fig. 7). The high glucose–induced JAK2 activation
in failing myocytes was inhibited by 52% when the cells
were preincubated with ramipril (P  0.01 vs. buffer with
high glucose) (Fig. 7), thus indicating that tyrosine phos-
phorylation was mediated by neo-formed Ang II. JAK2
activation was also prevented by preincubation with DPI
(Fig. 7), tiron, apocynin, and rotenone.
The different response between failing and nonfailing
myocytes was not due to different Ang II surface receptor
populations because Ang II receptor binding on ventricu-
lar myocytes was not significantly different from nonfailing
myocytes (Table 2). RT-PCR studies confirmed at the
mRNA level the results obtained in binding studies for AT1
and AT2 receptor subtypes (Fig. 8). Conversely, a signifi-
cant increase in both the AGTN and ACE mRNA ratios to
GAPDH (4.4  0.6–fold and 2.5  0.4–fold vs. nonfailing
cells, respectively) was found in failing cardiomyocytes.
DISCUSSION
The results of these experiments show that 1) in nonfailing
human ventricular myocytes Ang II activates JAK2 phos-
phorylation only in the presence of high glucose, which
enhances ROS generation, whereas 2) in failing myocytes,
high glucose per se induces JAK2 phosphorylation via an
ACE-dependent Ang II autocrine production.
High glucose enhances Ang II–induced JAK2 activa-
tion in nonfailing myocytes. Clinical studies have
shown that in diabetic patients the inhibition of RAS may
offer additional specific vascular and renal protection,
beyond the lowering of blood pressure (23). A close link
was reported to exist between high glucose, Ang II myo-
cyte formation, and activation of intracellular pathway of
death signaling (6). In particular, in rat cardiomyocytes
high glucose induces enzymatic glycosylation of p53,
which in turn activates Ang II production leading to p38
MAPK phosphorylation (6). In humans, diabetic cardiomy-
opathy is also characterized by myocyte hypertrophy (4).
However, experimental studies in rats indicate that glu-
cose induces only the phosphorylation of Jun NH2-termi-
nal kinase (JNK) (6), which plays a minor role in myocyte
hypertrophy (24), whereas the MAPK pathway mainly
related with myocyte hypertrophy (ERK1/2) (7,8) re-
mained unaffected (6). No information was available re-
garding the response of a different intracellular pathway
activated by JAK2 phosphorylation, which is known to
play a relevant role in myocyte hypertrophy (25,26). There-
fore, the observation that high glucose enhances Ang
II–mediated JAK2 phosphorylation in nonfailing myocytes
extend previous results revealing the possible involvement
in diabetic cardiomyopathy of an intracellular pathway
distinct from MAPK.
The second observation is that at variance with that
reported in other cell types (10) and in neonatal myocytes
(11–13), the stimulation of AT1 receptor subtype does not
activate JAK2 in nonfailing human adult ventricular cardi-
omyocytes. The capability of the AT1 receptor to bind to
the intracellular tyrosine kinase JAK2 was demonstrated
and the AT1 receptor is known to contain a YIPP (tyrosine-
isoleucine-proline-proline amino acids 319–322) motif in
the cytoplasmic tail that may recruit JAK2 (27). However,
although the biochemical structure creates a signaling
complex mechanistically similar to that observed with
growth factor and cytokine receptors, in our human adult
myocytes, Ang II evoked a JAK2 response only in the
presence of high glucose. Thus, a discrepancy exists
FIG. 3. A: Effects of 6-h incubation with Ang II (100 nmol/l) on the
phosphorylated–to–total JAK2 ratio (*P < 0.01 vs. baseline). B: Rep-
resentative Western blots performed with specific anti-JAK2 (JAK2)
and anti–phospho-JAK2 (p-JAK2) antibodies on lysates of myocytes
incubated for 6 h with Ang II (100 nmol/l) in DMEM containing either
normal glucose (5.5 mmol/l) or high glucose (25 mmol/l) at the same
final normal osmolarity. High osmolarity was obtained by adding 19.5
mmol/l of glucose (high glucose) or mannitol (M) to normal osmolarity
normal glucose buffer.
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between the response of neonatal cells and the close
control over AT1-mediated JAK2 activation, which seems
to operate in human adult ventricular myocytes. The
different response might be related with the higher activity
of intracellular phosphatase in adult than in neonatal cells
(28). In the present study we did not measure the response
of intracellular phosphatase to Ang II stimulation. How-
ever, phosphatase likely plays a minor role in Ang II–
induced JAK2 response in the presence of high glucose
because, although AT2 receptor subtype was reported to
enhance phosphatase activity (29,30), the AT2 blockade
failed to enhance JAK2 phosphorylation. A second possi-
ble relevant regulator of JAK2 response is represented by
ROS. The capability of ROS to mediate JAK2 phosphory-
lation was observed in other cell types, such as fibroblasts
and A-431 cells (31) and in aortic smooth muscle cells
(10,32). In the present study the critical role of ROS also in
human cardiomyocytes was demonstrated by the effects of
tiron (a cell-permeable O2 scavenger) and DPI (a nonspe-
cific flavoprotein inhibitor). In the heart, NADPH oxidase
is considered to be the main source of Ang II–induced O2
production (10,33), but other possible sources of ROS in
FIG. 4. Ang II–induced JAK2 phosphorylation in nonfailing human ventricular cardiomyocytes in the presence of high glucose concentrations is
mediated by AT1 receptor subtype and ROS production. A: Representative Western blots obtained from nonfailing myocytes incubated in the
presence of normal glucose or high glucose. Positive control was performed by stimulating nonfailing myocytes with interleukin-6 (10 ng/ml).
Negative control was obtained in the presence of competing peptide (CP). Effects of AT1 (1 mol/l valsartan) or AT2 (1 mol/l PD123319)
receptor antagonism and inhibition of ROS generation (100 mol/l DPI). B and C: Phosphorylated–to–total JAK2 ratio quantitated from all
experiments. Increases of p-JAK2–to–JAK2 ratio versus baseline (B) in normal glucose () and high glucose (f), and percent of inhibition of
p-JAK2–to–JAK2 ratio versus Ang II in high glucose medium (C). Data are means  SD.*P < 0.01.
FIG. 5. Representative Western blots obtained from nonfailing myo-
cytes incubated in high glucose and stimulated with Ang II in the
presence of DPI (100 mol/l), tiron (100 mol/l), apocynin (10 mol/l),
and rotenone (roten.; 5 mol/l).
FIG. 6. A: Representative Western blots performed with anti–phospho-
JAK2 (p-JAK2) and anti-JAK2 (JAK2) antibodies in myocytes ob-
tained from two nonfailing (NF) and two failing hearts (FH) incubated
for 6 h in the presence of normal glucose and high glucose. B: Increase
in phosphorylated–to–total JAK2 ratio versus baseline in myocyte
incubated in normal glucose () and high glucose (f). Data are
means  SD. *P < 0.01 vs. normal glucose.
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diabetes are known to exist. In particular, in different cell
types high glucose was reported to induce O2 generation
not only via NADPH oxidase but also by mitochondrial
oxidase (34). A possible participation of both NADPH and
mitochondrial source seems to exist because the same
inhibitory response was obtained in the presence of both
apocynin, which blocks the association of p47phox cyto-
solic subunit with the NADPH oxidase membrane (35),
and rotenone, which inhibits NADH dehydrogenase in
mitochondrial complex I (36).
The time course of JAK2 activation by Ang II in the
presence of high glucose appears to be a relatively late
event when compared with previous studies performed in
different cell types (14,37). However, in contrast with the
quoted studies in which cells were preincubated in high
glucose or normal glucose for long durations (up to 24 h)
before the addition of Ang II, in our study the time course
started after the addition of both high glucose and Ang II.
Thus, it is conceivable that the late response of JAK2
phosphorylation may be due to the time required by
glucose to increase ROS generation.
Therefore, these experiments, although they do not
solve the question of whether in nonfailing human myo-
cytes the capability of Ang II to induce ROS generation is
limited or whether the ROS generated are promptly inac-
tivated, clearly indicate that high glucose may allow Ang II
to reach a threshold level of ROS necessary to activate
JAK2.
The effects of Ang II in the presence of high glucose
might also have clinical relevance owing to the early
increase in Ang II cardiac generation in response to
hemodynamic overload (38) or in asymptomatic patients
in a very early phase of heart failure (20). The effects of a
persistent increase of cardiac Ang II generation on growth
factors production and collagen deposition (39) might thus
be amplified in diabetic subjects. In particular, the close
relationship between mechanical forces and cardiac Ang II
generation stress the importance of reaching a low target
of blood pressure in diabetic individuals.
Role of Ang II in glucose-induced JAK2 activation in
failing myocytes. The present results show that failing
myocytes, unlike those from nonfailing cells, respond to
high glucose with JAK2 activation even in the absence of
exogenous Ang II. The capability of AT1 antagonism to
inhibit high glucose–induced JAK2 activation agrees with
previous studies performed in rat cardiomyocytes that
demonstrated the capability of glucose to induce Ang II
formation (6). An important aspect revealed by the present
study is that the same response is antagonized also by an
ACE inhibitor. This result strongly suggests that Ang
II–activating JAK2 is newly synthesized by myocytes and
that ACE is a relevant source of Ang II formation in human
failing myocytes. Other studies indicated that chymase
rather than ACE is a major determinant for local Ang II
generation in cardiac tissue (18). However, the expression
of mRNA for ACE rather than chymase was reported to be
increased in the myocardium of patients with heart failure
(20). The limit of all these studies is mainly related to the
absence of any information regarding isolated cardiomyo-
cytes. The only study investigating this aspect was per-
formed in animals (dogs) with experimental heart failure
(pacing) and reported an increased expression of mRNAs
for the RAS components regulating Ang II formation
(angiotensinogen, renin, and ACE) in failing cardiom-
yoctes without any changes in chymase gene expression
(40). The present study reveals for the first time that
human ventricular cardiomyocytes express mRNAs for all
the components of the RAS and that the progression to
heart failure is characterized by marked overexpression of
angiotensinogen and ACE with no changes in the expres-
FIG. 7. A: High glucose–induced JAK2 phosphorylation in human
ventricular myocytes isolated from failing hearts. B: Myocytes were
incubated in normal glucose () or high glucose (f) in the presence of
buffer or AT1 (1 mol/l valsartan) and AT2 (1 mol/l PD123319)
receptor antagonists, ACE inhibitor (100 nmol/l ramipril), and inhibi-
tor of ROS generation (100 mol/l DPI).
FIG. 8. Representative PCRs performed with total RNA isolated from
myocytes obtained from two nonfailing hearts (NF) and two failing
hearts (FH) using specific primers for GAPDH, ACE, chymase, AT1 and
AT2 receptor subtypes, and AGTN.
TABLE 2
Characterization of Ang II receptors on isolated myocytes
Nonfailing
Dilated
cardiomyopathy
Bmax Total (fmol/mg) 0.57 0.21 0.60 0.11
Kd (nmol/l) 0.19 0.08 0.23 0.10
AT1:AT2 79:21 73:27
Bmax AT1 receptor (fmol/mg) 0.45 0.17 0.44 0.08
Bmax AT2 receptor (fmol/mg) 0.12 0.04 0.16 0.05
Data are means  SE.
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sion of chymase. Although these results do not exclude
that both enzymes may be involved in Ang II formation in
failing myocytes, the comparable effect of AT1 antagonist
and ACE inhibition on JAK2 phosphorylation suggests that
in this condition ACE may represent the major pathway
for myocyte Ang II formation.
Experiments performed with the different ROS inhibi-
tors indicate that also in failing myocytes ROS generation
mediates high glucose–induced JAK2 phosphorylation.
Therefore, also in failing adult myocytes, ROS generation
is a determinant for Ang II to induce JAK2 activation. The
enhanced ROS generation might be particularly relevant in
human failing hearts where NADPH oxidase, which is
recognized as a major source of ROS, is known to be
overactivated (41).
The second relevant difference observed in failing myo-
cytes is that, at variance with nonfailing cells, Ang II
induces JAK2 activation also in the presence of normal
glucose concentration. The two Ang receptor subtypes
mediate opposite intracellular effects in cardiomyocytes
because AT1 was reported to activate NADPH oxidase
(41–43), JAK2 (9,10,27), and MAPK phosphorylation (44),
whereas AT2 was shown to antagonize AT1 effects by
activating MAPK-1 phosphatase (29,30). The different pat-
tern of response between failing and nonfailing cells
appears undue to a different expression of Ang II recep-
tors, because failing and nonfailing cells share the same
absolute number and relative AT1–to–AT2 receptor ratio
at both protein and mRNA levels. On the other hand, the
different JAK2 response to Ang II stimulation is unlikely
due to the participation of a different source of ROS.
Antioxidant enzymes are decreased in the failing heart
(33,41), so that it cannot be excluded that high glucose–
induced superoxide generation may be increased in myo-
cytes isolated from failing hearts.
In conclusion, although we did not investigate the
activation of different STATs (signal transducer activators
of transcription) following JAK2 phosphorylation in either
nonfailing or failing hearts, our results may have relevant
clinical implications. The capability of high glucose to
allow Ang II to activate an important pathway for myocyte
hypertrophy in nonfailing hearts may offer a reason for the
importance of the strict blood pressure control in diabetic
individuals. On the other hand, the capability of glucose to
directly enhance Ang II release in failing hearts and to
activate a pathway that is also related to intracellular
signaling of inflammation indicates that high glucose can
directly amplify diabetic cardiac complications.
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